Increasing the power of tumour control and normal tissue complication probability modelling in radiotherapy: recent trends and current issues(132 visite)(PDF pubblico59 visite) Tommasino F, Nahum A, Cella L
Transl Cancer Res, 2017; N/D: N/D-N/D.
Tipo di articolo: Journal Article,
Impact factor: 1.167, Impact factor a 5 anni: 0
Url: Non disponibile.
Parole chiave: Non disponibili.
Affiliazioni:
*** IBB - CNR ***
Riferimenti:
Non disponibile.
The release of a homogeneous high dose to the tumour region has been one<br> of the cornerstones of radiotherapy (RT) treatment since its early <br>days. According to the organ type and to the cancer histology, different<br> doses are required in order to inactivate malignant cells, thus <br>stopping proliferation. However, radiation-induced cell killing is a <br>stochastic process. Tumour control probability (TCP) models have been <br>developed in order to assign a success rate to a given RT treatment. At <br>the same time, there is the need to keep the risks of normal tissue <br>toxicity at an acceptable level. Normal tissue complication probability <br>(NTCP) models provide a means of doing this. Traditionally, TCP and NTCP<br> models combine clinical outcomes with dosimetric information in terms <br>of dose-volume histograms (DVH). Model parameters are derived by <br>mathematical fits to clinical observations and are subsequently used to <br>estimate the risk of tumour relapse or toxicity. In both types of <br>models, all of the patient dosimetric information is condensed into the <br>DVHs, which represents a potential limitation on their descriptive and <br>predictive power. This choice, related to historical and practical <br>reasons, does not allow the full complexity of the 3D dose distribution <br>in the patient to be taken into account. Neglecting these aspects might <br>be relevant in a modern RT setting, which often includes the presence of<br> high dose gradient regions. This has motivated research on ‘advanced’ <br>TCP and NTCP models, able to tackle the problem by looking at a <br>different scale, e.g. in tumour sub-regions or at the single voxel <br>level. This is relevant not only from the purely dosimetric point of <br>view. Increasing evidence is reported on the heterogeneity of cancer <br>tissues, suggesting that non-uniform dose distributions could result in <br>improved survival, for instance if targeted to take into account sub <br>volumes with high clonogen density or hypoxic radioresistant regions. <br>Similarly, radiation-induced side effects are part of a complex <br>biological response, which depends not only on cell killing, but also on<br> the inflammatory response and in some cases on the interplay among <br>different organs. Obviously, conventional NTCP models cannot describe <br>this scenario, and the development of more advanced mathematical tools <br>is needed. This review will be focused on the discussion of recent <br>studies showing possible directions for moving the field of TCP and NTCP<br> modelling forward. Without diminishing the role and usefulness of <br>available models, the aim is to shed light on the benefits that might be<br> achieved by ‘enhanced’ modelling. This could represent an important <br>step in the gradual transition of radiation therapy towards a form of <br>precision medicine.
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(20 visite) NEW ENGL J MED (ISSN: 0028-4793), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 DettagliEsporta in BibTeXEsporta in EndNote
Testino G, Leone S, Fagoonee S, Del Bas JM, Rodriguez B, Puiggros F, Marine S, Rodriguez MA, Morina D, Armengol L, Caimari A, Arola L, Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-gentilucci U, Cavallo MG, Morini S, Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV, Lee SM, Jun DW, Cho YK, Jang KS, Kucukazman M, Ata N, Dal K, Yeniova AO, Kefeli A, Basyigit S, Aktas B, Akin KO, Agladioglu K, Ure OS, Topal F, Nazligul Y, Beyan E, Ertugrul DT, Catena C, Cosma C, Camozzi V, Plebani M, Ermani M, Sechi LA, Fallo F, Goto Y, Ray MB, Mendenhall CL, French SW, Gartside PS Serum vitamin A deficiency and increased intrahepatic expression of cytokeratin antigen in alcoholic liver disease(6 visite) Hepatology (ISSN: 1827-1669electronic, 0026-4806linking), 1988 Sep; 83120693611123109(5): 1019-1026. Impact Factor:0.913 DettagliEsporta in BibTeXEsporta in EndNote
181 Records (152 escludendo Abstract e Conferenze). Impact factor totale: 642.396 (564.089 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 696.811 (611.181 escludendo Abstract e Conferenze).
ibb.cnr.it
